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Rapid identification of isolates in positive blood cultures are of great importance to secure correct
treatment of septicaemic patients. As antimicrobial resistance is increasing, rapid detection of
resistance is crucial. Carbapenem resistance in Bacteroides fragilis associated with cfiA-encoded
class B metallo-beta-lactamase is emerging. In our study we spiked blood culture bottles with 26
B. fragilis strains with various cfiA-status and ertapenem MICs. By using main spectra specific for
cfiA-positive and cfiA-negative B. fragilis strains, isolates could be screened for resistance. To
verify strains that were positive in the screening, a carbapenemase assay was performed where
the specific peaks of intact and hydrolysed ertapenem were analysed with matrix-assisted laser
desorption ionization–time of flight mass spectrometry (MALDI-TOF MS). We show here that it is
possible to correctly identify B. fragilis and to screen for enzymic carbapenem resistance directly
from the pellet of positive blood cultures. The carbapenemase assay to verify the presence of the
enzyme was successfully performed on the pellet from the direct identification despite the
presence of blood components. The result of the procedure was achieved in 3 h. Also the Bruker
mass spectrometric b-lactamase assay (MSBL assay) prototype software was proven not only to
be based on an algorithm that correlated with the manual inspection of the spectra, but also to
improve the interpretation by showing the variation in the dataset.
INTRODUCTION
Today it is obvious that matrix-assisted laser desorption
ionization–time of flight mass spectrometry (MALDI-TOF
MS) is an impressive technique for species identification,
and it has been fully accepted and introduced in many
microbiology laboratories all over the world. It has
revolutionized routine work by its rapidness, and the
fast recognition of bacteria directly from positive blood
cultures is an application proving to be a very useful tool
(Martiny et al., 2012). When treating patients with septic
shock, a delay in implementing the appropriate anti-
microbial treatment will considerably reduce the average
survival of the patient (Kumar et al., 2009). Martiny et al.
(2013) showed in their study that the introduction of direct
identification (direct ID) from blood cultures led to
modification of therapy in 13.38% of adult patients, and
in 37.50% of paediatric patients a suspected contaminant
could be confirmed.
When performing species identification with MALDI-
TOF MS, a unique spectrum for that particular strain is
generated, and that spectrum might contain more informa-
tion other than species identity. There are several publica-
tions showing this type of reanalysis or subtyping (Griffin
et al., 2012; Josten et al., 2013; Nagy et al., 2013). Nagy et al.
(2011a) showed the possibility to separate Bacteroides
fragilis strains that carry the cfiA gene from those that do
not. By generating cfiA-specific main spectra (MSP), strains
can easily be screened for the possible presence of a beta-
lactamase.
The activity of the carbapenemase can be verified with a
hydrolysis assay performed with MALDI-TOF MS, and we
have published a successful assay using ertapenem as a
substrate for carbapenemase producing B. fragilis (Johansson
et al., 2014). Recently Jung et al. (2014) published a paper
showing the possibility to perform hydrolysis assay from the
Abbreviations: MALDI-TOF MS, matrix-assisted laser desorption ioniza-
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pellet being generated when performing direct ID from
blood cultures.
In this paper we are focusing on B. fragilis, which is a
strictly anaerobic rod found in the gut. It carries several
virulence factors and members of the B. fragilis group are
the most frequent anaerobes found in blood cultures
(Lombardi & Engleberg, 1992). Antimicrobial resistance or
reduced susceptibility has for a long time been considered
rare in B. fragilis, but the reported numbers of resistant
strains are growing (Nagy et al., 2011b). Multidrug resistant
(MDR) B. fragilis has been reported (Sherwood et al., 2011;
Kalapila et al., 2013), and a study from Justesen et al. (2013)
showed that 10.2% of B. fragilis strains in blood cultures
from several Danish hospitals carried the cfiA gene, which
encodes a carbapenemase. Since antimicrobial testing
of anaerobes is more time-consuming and often more
expensive, a rapid and accurate method to detect carbape-
nemase production in these strains is of great importance.
We present here an optimal scenario where B. fragilis
is rapidly identified from a positive blood culture and
instantly screened for the presence of cfiA-gene within
an hour, followed by the verification of carbapenemase
activity, by performing an ertapenem hydrolysis assay in
less than 3 h.
METHODS
Twenty-six isolates of B. fragilis were analysed (see Table 1). All
strains were examined for the presence or absence of the cfiA gene by
end point PCR (previously described by So´ki et al., 2004a, 2006). The
set-up consisted of 15 cfiA-positive and 11 cfiA-negative isolates with
various ertapenem MICs. To confirm correct species all isolates were
cultivated on fastidious anaerobic agar (LAB-M) overnight in 35 uC
in an anaerobic environment and identified to species level using the
Microflex and the MALDI Biotyper 3.1 software (Bruker Daltonics)
according to the manufacturer’s instructions. A score value of ¢2.0
was considered as a secure species level identification. Susceptibility
testing was performed for ertapenem using Etest (bioMe´rieux)
and results interpreted according to European Committee on
Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoints.
Carbapenemase production was verified with spectrophotometric
assay (So´ki et al., 2006).
Blood culture and direct identification (direct ID). To simulate a
true blood culture, with all blood components that might disturb the
analysis, BD BACTEC Plus/Anaerobic/F bottles (Becton Dickinson)
were inoculated with 5 ml of human blood (outdated blood
components donated from Transfusion medicine at Central hospital
Va¨xjo¨) and 10 ml of bacterial suspension of McFarland 0.5 in 0.9%
NaCl. Bottles were incubated in a BD BACTEC FX (Becton Dickinson)
until positive signalling from the system was obtained. As control, a
bottle containing blood without bacteria was used and incubated for
24 h. Direct identification was performed according to the published
protocol by Martiny et al. (2013) with the modification of adding 1 ml
of 70% formic acid on the spotted target plate before applying 1ml
HCCA matrix (2.5 mg a-cyano-4-hydroxycinnamic acid dissolved in
50% acetonitril, 47.5% HPLC-pure H2O and 2.5% trifluoroacetic
acid; Bruker Daltonics) and left to dry. Identification was performed
according to the manufacturer’s instructions in the MALDI Biotyper
3.1 software (Bruker Daltonics). Scores generated from the direct ID
are presented in Tables 1 and 2.
Screening for cfiA-positive isolates. Each of the spectra generated
at identification was uploaded in the MALDI Biotyper OC software
(Bruker Daltonics) and blasted against the previously published cfiA-
positive and cfiA-negative MSP (Nagy et al., 2011a). Score values
from this BLAST are presented in Tables 1 and 2. Getting the cfiA-
positive MSP as first best match and with a log score difference of
.0.3 to the second best match was sufficient to consider the isolate
cfiA-positive in the screening.
Ertapenem hydrolysis assay. The pellet generated when perform-
ing direct ID was resuspended in 20 ml 10 mM ammonium hydrogen
citrate buffer (pH 7.1) dissolved in water (Sigma-Aldrich) containing
0.05 mg ertapenem ml21 (Invanz, MSD). As controls, ertapenem-
containing (0.05 mg ml21) cell-free buffer solutions were applied
(ertapenem only), as well as pellets generated from bacteria-free
blood-containing blood culture bottles (ertapenem and blood).
All suspensions were incubated at 35 uC on a shaker for 2 h. After
incubation, the suspensions were centrifuged at 13 400 g for 2 min.
Two microlitres of the supernatant were spotted on a polished steel
target plate (Bruker Daltonics), left to dry and then overlaid with 1 ml
HCCA matrix (Bruker Daltonics).
All measurements were performed on a Microflex (Bruker Daltonics)
mass spectrometer. The parameter settings were: ion source 1,
19.0 kV; ion source 2, 17.2 kV; lens, 6.0 kV; detector gain, 2.5 kV.
Spectra were recorded in the mass range of 0–1000 Da with 60 Hz
laser frequency. Each spectrum was obtained from 240 laser shots. For
calibration, the peptide calibration standard II (Bruker Daltonic) was
used. The peaks employed for calibration were the HCCA peaks
[M+H]+ at 190.05 Da, [2M+H]+ at 379.09 Da and the bradykinin
(1–7) peak [M+H]+ at 757.40 Da.
The analysis of MALDI-TOF MS spectra was performed using the
Flexanalysis 3.3 software (Bruker Daltonics). The spectra were
smoothed and baseline subtracted and then manually examined for
the specific ertapenem related peak patterns in the mass range of
4–600 Da. The hydrolysis spectra were also tested against the
prototype software developed by Bruker Daltonics.
RESULTS AND DISCUSSION
Since blood components might disturb the identification as
well as the hydrolysis assay, we chose to inoculate the blood
culture bottles with human blood, to simulate a true blood
culture. The spiked blood cultures were incubated in the
BD BACTEC FX and became positive in the range of 12–
30 h. Bottles were then removed from the BACTEC FX at
various time points resulting in different total incubation
times. There was no correlation with log score value from
direct ID and incubation time in this set-up.
Direct ID from positive blood cultures by MALDI-TOF MS
is routinely performed at the Department of Clinical
Microbiology at Central hospital in Va¨xjo¨, and the spiked
bottles were treated as any other positive blood culture
according to the previously described protocol (Martiny
et al., 2013). Score values from direct ID of the B. fragilis
strains are presented in Tables 1 and 2, and ranged between
1.865 and 2.414. A local algorithm allows score values.1.7
to be considered as secure level species identification when
performing direct ID; however 24 of 26 B. fragilis strains
had a score value .2, which is considered a secure level for
species identification by the assay manufacturer. This high
score value despite the disturbing blood components fits
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Table 1. cfiA-positive B. fragilis strains used in the study with direct ID scores from positive blood cultures, cfiA-specific MSP BLAST scores and hydrolysis assay results
Increased MIC values (due to growth of micro-colonies in the ellipse) after 48 h incubation are shown in parentheses.
B. fragilis PCR detection
of cfiA gene
IS element* Direct ID
(log score)
cfiA + specific
MSP (log score)
cfiA – specific
MSP (log score)
Ertapenem
hydrolysis
Ertapenem
MIC (mg l”1)
Reference
TAL3636 + IS942 2.199 2.396 1.621 + .32 Rasmussen et al. (1990)
1672 + IS1186 2.12 2.39 1.792 + .32 So´ki et al. (2004a)
2944 + IS614B 2.022 2.046 1.782 + .32 So´ki et al. (2004a)
1776 + IS1187 2.034 2.239 1.397 + .32 So´ki et al. (2004a)
2685 + IS614B 2.04 2.25 1.289 + .32 So´ki et al. (2004a)
4729 + IS1187 2.142 2.147 1.312 + .32 So´ki et al. (2004a)
6712 + IS612B 2.163 2.314 1.205 + .32 So´ki et al. (2004a)
16997 + – 2.129 2.272 1.56 + 16 So´ki et al. (2004a)
388 + – 2.027 2.112 1.493 + 2 So´ki et al. (2004a)
BF8 (BFr81) + – 2.173 2.281 1.554 + 4 Podglajen et al. (1992)
72 + – 2.169 2.262 1.703 + 2 Nagy et al. (2001)
55474/1 + – 1.995 2.188 1.76 + 2 Johansson et al. (2014)
22 + – 2.239 2.298 1.889 + 2 Nagy et al. (2001)
AA-137-TH + -– 1.865 1.826 1.431 + 2 (32) Johansson et al. (2014)
12-538566 + – 2.115 2.338 1.539 + 1 (8) Johansson et al. (2014)
*IS element upstream of the cfiA gene.
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well with a local evaluation of direct ID of rapidly growing
Gram-negative rods (data not shown). The direct ID
performed from the bacteria-free blood-containing blood
culture bottle generated a score value of 1.299 proving that
blood components give rise to spectra that might have a
negative impact on generated spectra from direct ID.
However, in this particular case, the score values from the
tested B. fragilis strains were undisputable.
Immediately after direct ID the generated ID-spectra were
uploaded in the Biotyper OC software and blasted against
the two cfiA-specific MSPs already described in the paper
from Nagy et al. (2011a). All the cfiA-positive strains were
correctly assigned to the cfiA-positive MSP as first best
match with score values ranging between 1.826 and 2.396
(Table 1). Naturally, the cfiA-negative MSP were assigned
as second best match with score values ranging between
1.205 and 1.889 (Table 1). The log score difference between
first and second best match ranged between 0.4 and 1.11.
All the cfiA-negative strains were correctly assigned to the
cfiA-negative MSP as first best match with score values
ranging between 2.163 and 2.465 (Table 2). As second best
match, the cfiA-positive MSP were presented with score
values ranging between 1.472 and 1.732 (Table 2). The log
score difference between first and second best match ranged
between 0.53 and 0.96. This simple and fast reanalysis of
generated spectra acts as a screening of the strains and made
it possible to sort out potential carbapenemase producers.
At this stage it would also be a great advantage to alert the
clinician about the possible presence of a carbapenemase
producing B. fragilis in positive blood cultures.
To verify the positive screening results, the presence of
carbapenemase needed to be proven. All strains were tested
in a hydrolysis assay with MALDI-TOF MS where the
intact or hydrolysed forms of ertapenem were studied.
Initially the strains were tested according to our published
protocol using an ertapenem concentration of 0.5 mg ml21
(Johansson et al., 2014). However this concentration was
probably too high compared with the amount of bacteria
in the direct ID pellet since only partial hydrolysis was seen
after 2 h incubation (data not shown). All strains were then
tested with a 10-fold lower concentration, 0.05 mg ml21,
and hydrolysis was clearly seen in all the cfiA-positive
strains by the presence of the following peak pattern (m/z):
450.5, 472.5, 494.5, 516.5 and 438.5 Da, proving the
activity of the carbapenemase. No hydrolysis was seen in
the cfiA-negative strains or blood only, which was proven
by the presence of intact ertapenem with the following peak
pattern (m/z): 476.5, 498.5, 520.5 and 542.5 Da.
Notable is the fact that some of the B. fragilis strains had
a quite low MIC for ertapenem (MIC 2 mg l21) but
showed hydrolysis of ertapenem in the hydrolysis assay.
After prolonged incubation (48 h) of the Etests, the MIC
increased due to micro-colonies in the ellipse. The presence
of similar micro-colonies has been described by So´ki et al.
(2004b). In Table 1, these variable MICs are shown in
parentheses.T
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The hydrolysis spectra were manually and qualitatively
evaluated, giving a result of hydrolysis or no hydrolysis.
However, the spectra were also tested with prototype
software from Bruker Daltonics where the spectra were
calculated with the following formula logRQ5log (sum
of hydrolysed peak intensities)/(sum of non-hydrolysed
peak intensities). This approach visualized a much
more dynamic result of the hydrolysis assay (Fig. 1). The
cfiA-negative strains (n511) as well as blood only and
ertapenem only ended up with a logRQ ,0.25, which
clearly separated them from the other strains, comparable
with manual examination of the spectra. But within
the cfiA-positive population there was a separation that
correlated with the MICs. Strains (eight isolates) with
lower MICs (2–16 mg l21) had lower logRQ values
(between 0.25 and 0.75), which means slower hydrolysis.
All strains (seven isolates) with MICs .32 mg l21 had the
highest logRQ values (.0.75), with one exception. Strain
1776 showed a lower logRQ, comparable with strains
with lower MICs. When repeating the experiment, the
strain ended up with a similar logRQ score. One can
only hypothesize that this strain might have a porin defect
that prevents ertapenem from entering into the periplas-
matic space, lowering the logRQ value. The software
prototype was only tested with this small collection of
strains, and it is difficult to fully draw any conclusions
regarding the dynamics within the cfiA-positive popu-
lation, even though it was repeatable with these particular
strains.
To summarize, the method presented here not only
allows the direct ID of the B. fragilis strains from positive
blood cultures, but combined with of the use of the
MALDI Biotyper OC software and the ertapenem hydro-
lysis assay with manual or automated evaluation, but also
can very rapidly answer the question of whether carbape-
nems can be used for the treatment of an infection leading
to sepsis.
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